To clear or to fear: An innate perspective on factor VIII immunity

Cellular Immunology

Volumn 301, Issue , 2016, Pages 82-89

  Lai, Jesse Derek ^a   Georgescu, Maria Teofana ^a   Hough, Christine ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Antigen presenting cells; Clearance; Factor VIII; Hemophilia A; Immune tolerance; Inhibitors; Innate immunity

Indexed keywords

BLOOD CLOTTING FACTOR 8; LECTIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTITUTION THERAPY; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; ANTIGEN PRESENTATION; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE;

EID: 84959219665     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.10.011     Document Type: Article

References (111)

1. Mannucci P., Tuddenham E. The Hemophilias - From Royal Genes to Gene Therapy. New Engl. J. 2001, 344:1773-1779.
2. Rosendaal F., Smit C., Briet E. Hemophilia treatment in historical perspective: a review of medical and social developments. Ann. Hematol. 1991, 62:5-15.
3. Hay C.R.M. The epidemiology of factor VIII inhibitors. Haemophilia 2006, 12(Suppl. 6):23-28. discussion 28-9.
4. Gouw S.C., van der Bom J.G., Ljung R., Escuriola C., Cid A.R., Claeyssens-Donadel S., et al. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med. 2013, 368:231-239.
5. Gouw S.C., van den Berg H.M., Fischer K., Auerswald G., Carcao M., Chalmers E., et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013, 121:4046-4055.
6. Gouw S.C., van der Bom J.G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-4654.
7. Eckhardt C.L., van Velzen A.S., Peters M., Astermark J., Brons P.P., Castaman G., et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013, 122:1954-1962.
8. Van den Berg H.M., Chalmers E.A. Clinical prediction models for inhibitor development in severe hemophilia A. J. Thromb. Haemost. 2009, 7(Suppl. 1):98-102.
9. Astermark J., Berntorp E., White G.C., Kroner B.L. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001, 7:267-272.
10. Hay C.R., Ollier W., Pepper L., Cumming A., Keeney S., Goodeve A.C., et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb. Haemost. 1997, 77:234-237.
11. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.-K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-3172.
12. Astermark J., Oldenburg J., Carlson J., Pavlova A., Kavakli K., Berntorp E., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-3745.
13. Astermark J., Wang X., Oldenburg J., Berntorp E., Lefvert A.K. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A [1]. J. Thromb. Haemost. 2007, 5:263-265.
14. Kempton C.L., White G.C. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009, 113:11-17.
15. Wroblewska A., Reipert B.M., Pratt K.P., Voorberg J. Dangerous liaisons: how the immune system deals with factor VIII. J. Thromb. Haemost. 2013, 11:47-55.
16. van Haren S.D., Wroblewska A., Fischer K., Voorberg J., Herczenik E. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Rev. 2012, 26:43-49.
17. Fijnvandraat K., Peters M., Ten Cate J.W. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br. J. Haematol. 1995, 91:474-476.
18. Fay P.J., Coumans J.V., Walker F.J. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J. Biol. Chem. 1991, 266:2172-2177.
19. Koppelman S.J., van Hoeij M., Vink T., Lankhof H., Schiphorst M.E., Damas C., et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996, 87:2292-2300.
20. Cunningham M.A., Pipe S.W., Zhang B., Hauri H.P., Ginsburg D., Kaufman R.J. LMAN1 is a molecular chaperone for the secretion of coagulation factor VI11. J. Thromb. Haemost. 2003, 1:2360-2367.
21. Sodetz J.M., Pizzo S.V., McKee P.A. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J. Biol. Chem. 1977, 252:5538-5546.
22. Lenting P.J., Pegon J.N., Christophe O.D., Denis C.V. Factor VIII and von Willebrand factor-too sweet for their own good. Haemophilia 2010, 16(Suppl. 5):194-199.
23. Canis K., McKinnon T.A.J., Nowak A., McKinnon T.A.J., Nowak A., Haslam S.M., Panico M., Morris H.R., et al. Mapping the N-glycome of human von Willebrand factor. Biochem. J. 2012, 447:217-228.
24. Canis K., Mckinnon T.A.J., Nowak A., Panico M., Morris H.R., Laffan M., et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J. Thromb. Haemost. 2010, 8:137-145.
25. Vehar G., Keyt B., Eaton D., Rodriguez H. Structure of human factor VIII. Nature 1984, 312:337-342.
26. Medzihradszky K.F., Besman M.J., Burlingame A.L. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal. Chem. 1997, 69:3986-3994.
27. Mazsaroff I., Yu W., Kelley B.D., Vath J.E. Quantitative comparison of global carbohydrate structures of glycoproteins using lc-ms and in-source fragmentation. Anal. Chem. 1997, 69:2517-2524.
28. Fijnvandraat K., Berntorp E., ten Cate J.W., Johnsson H., Peters M., Savidge G., et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb. Haemost. 1997, 77:298-302.
29. Hironaka T., Furukawa K., Esmon P.C., Fournel M.A., Sawada S., Kato M., et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J. Biol. Chem. 1992, 267:8012-8020.
30. Thim L., Vandahl B., Karlsson J., Klausen N.K., Pedersen J., Krogh T.N., et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010, 16:349-359.
31. Zheng C., Liu H.H., Yuan S., Zhou J., Zhang B. Molecular basis of LMAN1 in coordinating LMAN1-MCFD2 cargo receptor formation and ER-to-Golgi transport of FV/FVIII. Blood 2010, 116:5698-5706.
32. Zhang B., McGee B., Yamaoka J.S., Guglielmone H., Downes K.A., Minoldo S., et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 2006, 107:1903-1907.
33. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconj. J. 2009, 26:231-245.
34. Padler-Karavani V., Yu H., Cao H., Chokhawala H., Karp F., Varki N., et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008, 18:818-830.
35. Macher B.A., Galili U. The Galα 1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 2008, 1780:75-88.
36. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12045-12050.
37. Kosloski M.P., Miclea R.D., Balu-Iyer S.V. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. 2009, 11:424-431.
38. Meeks S.L., Cox C.L., Healey J.F., Parker E.T., Doshi B.S., Gangadharan B., et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 2012, 120:2512-2520.
39. Noe D.A. A mathematical model of coagulation factor VIII kinetics. Pathophysiol. Haemost. Thromb. 1996, 26:289-303.
40. Schambeck C.M., Grossmann R., Zonnur S., Berger M., Teuchert K., Spahn A., et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb. Haemost. 2004, 92:42-46.
41. Navarrete A., Dasgupta S., Delignat S., Caligiuri G., Christophe O.D., Bayry J., et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J. Thromb. Haemost. 2009, 7:1816-1823.
42. van Schooten C.J., Shahbazi S., Groot E., Oortwijn B.D., van den Berg H.M., Denis C.V., et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008, 112:1704-1712.
43. Delignat S., Repessé Y., Navarrete A.M., Meslier Y., Gupta N., Christophe O.D., et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2012, 18:248-254.
44. Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 2010, 10:753-766.
45. Crispe I.N. The liver as a lymphoid organ. Annu. Rev. Immunol. 2009, 27:147-163.
46. Limmer A., Ohl J., Kurts C., Ljunggren H.G., Reiss Y., Groettrup M., et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 2000, 6:1348-1354.
47. Winau F., Hegasy G., Weiskirchen R., Weber S., Cassan C., Sieling P.A., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007, 26:117-129.
48. Burgio V.L., Ballardini G., Artini M., Caratozzolo M., Bianchi F.B., Levrero M. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology. Hepatology 1998, 27:1600-1606.
49. Kruse N., Neumann K., Schrage A., Derkow K., Schott E., Erben U., et al. Priming of CD4+ T cells by liver sinusoidal endothelial cells induces CD25low forkhead box protein 3- regulatory T cells suppressing autoimmune hepatitis. Hepatology 2009, 50:1904-1913.
50. Mebius R.E., Kraal G. Structure and function of the spleen. Nat. Rev. Immunol. 2005, 5:606-616.
51. Lai J., Cartier D., Van Velzen A., Hough C., Lillicrap D. Compared to B220/CD45R+ B lymphocytes, splenic dendritic cells and macrophages have limited propensity to bind factor VIII and demonstrate down-regulation of co-stimulatory molecules, In: Abstracts of the XXV Congress of the International Society of Thrombosis and Haemostasis. J. Thromb. Haemost. 2015, 13:140.
52. Gouw S.C., Van Der Bom J.G., Van Den Berg H.M., Zewald R.A., Ploos Van Amstel J.K., Mauser-Bunschoten E.P. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia 2011, 17:275-281.
53. Franchini M., Tagliaferri A., Mengoli C., Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit. Rev. Oncol. Hematol. 2012, 81:82-93.
54. Iorio A., Halimeh S., Holzhauer S., Goldenberg N., Marchesini E., Marcucci M., et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J. Thromb. Haemost. 2010, 8.
55. Qadura M., Waters B., Burnett E., Chegeni R., Bradshaw S., Hough C., et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009, 114:871-880.
56. Dasgupta S., Repessé Y., Bayry J., Navarrete A.-M., Wootla B., Delignat S., et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007, 109:610-612.
57. Hartholt R.B., Sorvillo N., Sedek M., ten Brinke A., van der Zwaan C., van Alphen F.P., et al. Surface bound von willebrand factor modulates factor VIII peptide presentation by dendritic cells, In: Abstracts of the XXV Congress of the International Society of Thrombosis and Haemostasis. J. Thromb. Haemost 2015, 13:834.
58. Algiman M., Dietrich G., Nydegger U.E., Boieldieu D., Sultan Y., Kazatchkine M.D. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:3795-3799.
59. Whelan S.F.J., Hofbauer C.J., Horling F.M., Allacher P., Wolfsegger M.J., Oldenburg J., et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013, 121:1039-1048.
60. Hofbauer C.J., Whelan S.F.J., Hirschler M., Allacher P., Horling F.M., Lawo J.-P., et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2014, 125:1180-1188.
61. Rastegarlari G., Pegon J.N., Casari C., Odouard S., Navarrete A.-M., Saint-Lu N., et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 2012, 119:2126-2134.
62. Lenting P.J., Neels J.G., van den Berg B.M., Clijsters P.P., Meijerman D.W., Pannekoek H., et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J. Biol. Chem. 1999, 274:23734-23739.
63. Saenko E.L., Yakhyaev A.V., Mikhailenko I., Strickland D.K., Sarafanov A.G. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J. Biol. Chem. 1999, 274:37685-37692.
64. Bovenschen N., Van Stempvoort G., Voorberg J., Mertens K., Meijer A.B. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain. J. Thromb. Haemost. 2006, 4:1487-1493.
65. Bovenschen N., Herz J., Grimbergen J.M., Lenting P.J., Havekes L.M., Mertens K., et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003, 101:3933-3939.
66. Herczenik E., van Haren S.D., Wroblewska A., Kaijen P., van den Biggelaar M., Meijer A.B., et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J. Allergy Clin. Immunol. 2012, 129:501-509. 509.e1-5.
67. Dasgupta S., Navarrete A.M., André S., Wootla B., Delignat S., Repessé Y., et al. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica 2008, 93:83-89.
68. Bovenschen N., Mertens K., Hu L., Havekes L.M., Van Vlijmen B.J.M. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005, 106:906-912.
69. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
70. Pawaria S., Binder R.J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2011, 2:521.
71. Gill J.C., Endres-Brooks J., Bauer P.J., Marks W.J., Montgomery R.R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69:1691-1695.
72. Pegon J.N., Kurdi M., Casari C., Odouard S., Denis C.V., Christophe O.D., et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 2012, 97:1855-1863.
73. Chang Y.C., Nizet V. The interplay between Siglecs and sialylated pathogens. Glycobiology 2014, 24:818-825.
74. Macauley M.S., Crocker P.R., Paulson J.C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 2014, 14:653-666.
75. Ali S.R., Fong J.J., Carlin A.F., Busch T.D., Linden R., Angata T., et al. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J. Exp. Med. 2014, 211:1231-1242.
76. Macauley M.S., Pfrengle F., Rademacher C., Nycholat C.M., Gale A.J., von Drygalski A., et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 2013, 123:3074-3083.
77. Connolly N.P., Jones M., Watt S.M. Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions. Br. J. Haematol. 2002, 119:221-238.
78. Crocker P.R., Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol. 2001, 22:337-342.
79. Bovenschen N., Rijken D.C., Havekes L.M., van Vlijmen B.J.M., Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J. Thromb. Haemost. 2005, 3:1257-1265.
80. Grewal P.K., Uchiyama S., Ditto D., Varki N., Le D.T., Nizet V., et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat. Med. 2008, 14:648-655.
81. Geijtenbeek T.B.H., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 2009, 9:465-479.
82. Dasgupta S., Navarrete A.-M., Bayry J., Delignat S., Wootla B., André S., et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8965-8970.
83. Rydz N., Swystun L.L., Notley C., Paterson A.D., Riches J.J., Sponagle K., et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013, 121:5228-5237.
84. Swystun L.L., Notley C., Sponagle K., James P.D., Lillicrap D. The endothelial lectin CLEC4M is a novel clearance receptor for factor VIII, In: Abstracts of the XXIV Congress of the International Society of Thrombosis and Haemostasis. J. Thromb. Haemost. 2013, 11:98.
85. Swystun L., Notley C., Sponagle K., James P.D., Lillicrap D. Regulation of factor viii clearance by mannose-binding lectins, In: Proceedings of the 2013 ASH Annual Meeting. Blood 2013, 122:2340.
86. Chan V.S.F., Chan K.Y.K., Chen Y., Poon L.L.M., Cheung A.N.Y., Zheng B., et al. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat. Genet. 2006, 38:38-46.
87. van Niel G., Wubbolts R., Stoorvogel W. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr. Opin. Cell Biol. 2008, 20:437-444.
88. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
89. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
90. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
91. Sousa C.E. Dendritic cells in a mature age. Nat. Rev. Immunol. 2006, 6:476-483.
92. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 2007, 7:19-30.
93. Kamphorst A.O., Guermonprez P., Dudziak D., Nussenzweig M.C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J. Immunol. 2010, 185:3426-3435.
94. Qadura M., Othman M., Waters B., Chegeni R., Walker K., Labelle A., et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J. Thromb. Haemost. 2008, 6:2095-2104.
95. Pfistershammer K., Stockl J. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb. Haemost. 2006, 96:309-316.
96. Moorehead P.C., Waters B., Sponagle K., Steinitz K.N., Reipert B.M., Lillicrap D. Surgical Injury alone does not provoke the development of factor VIII inhibitors in mouse models of hemophilia A, In: Proceedings of the 2012 ASH Annual Meeting. Blood 2012, 120:627.
97. Hashemi S.M., Fischer K., Gouw S.C., Rafowicz A., Carcao M., Platokouki H., et al. Do vaccinations influence the risk of inhibitor development in patients with severe hemophilia A?. J. Thromb. Haemost. 2015, 13:147.
98. Lai J., Moorehead P., Sponagle K., Steinitz K., Reipert B., Hough C., et al. Chemotactic antigen competition decreases the incidence of factor VIII inhibitors in hemophilia a mice immunized with influenza, with and without the adjuvant MF59C.1, In: Abstracts of the XXV Congress of the International Society of Thrombosis and Haemostasis. J. Thromb. Haemost. 2015, 13:68.
99. Hu G., Guo D., Key N.S., Conti-Fine B.M. Cytokine production by CD4 + T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb. Haemost. 2007, 97:304-309.
100. Ettinger R.A., James E.A., Kwok W.W., Thompson A.R., Pratt K.P. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009, 114:1423-1428.
101. van Haren S.D., Herczenik E., Ten Brinke A., Mertens K., Voorberg J., Meijer A.B. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol. Cell. Proteomics 2011, 10. M110.002246.
102. Pratt K.P., Thompson A.R. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin. Rev. Allergy Immunol. 2009, 37:80-95.
103. Verbij F.C., Fijnheer R., Voorberg J., Sorvillo N. Acquired TTP: ADAMTS13 meets the immune system. Blood Rev. 2014, 28:227-234.
104. Gilles J.G., Saint-Remy J.M.R. Healthy subjects produce both anti-Factor VIII and specific anti-idiotypic antibodies. J. Clin. Invest. 1994, 94:1496-1505.
105. Moorehead P.C., VanVelzen A., Sponagle K., Steinitz K.N., Reipert B.M., Lillicrap D. Co-administration of factor VIII and dexamethasone prevents anti-factor VIII antibody development in a mouse model of hemophilia A, In: Abstracts of the XXIV Congress of the International Society of Thrombosis and Haemostasis. J. Thromb. Haemost. 2013, 11:208-209.
106. Moorehead P.C., Georgescu M.T., Van Velzen A.S., Sponagle K., Vidal B., Reipert B.M., et al. Administration of dexamethasone during initial exposure to factor VIII induces durable and antigen-specific tolerance to factor VIII in hemophilia α mice with a humanized major histocompatibility complex II transgene, In: Proceedings of the 2014 ASH Annual Meeting. Blood 2014, 124:1489.
107. Georgescu M.T., Moorehead P.C., Sponagle K., Reipert B.M., Hough C., Lillicrap D. Administration of dexamethasone during initial exposure to factor VIII prevents the development of anti-factor VIII antibodies and increases the proportion of thymic but not splenic regulatory T cells in the exon 16 knockout C57Bl6 hemophilia Α mouse mode, In: Proceedings of the 2014 ASH Annual Meeting. Blood 2014, 124:237.
108. Waters B., Qadura M., Burnett E., Chegeni R., Labelle A., Thompson P., et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4 +CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 2009, 113:193-203.
109. Sherman A., Su J., Lin S., Wang X., Herzog R.W., Daniell H. Suppression of inhibitor formation against factor VIII in hemophilia A mice by oral delivery of antigens bioencapsulated in plant cells. Blood 2014, 124:1659-1669.
110. Swystun L.L., Notley C., Georgescu I., Sponagle K., Schledzewski K., Géraud C., et al. The scavenger receptor stabilin-2 (STAB-2) mediates clearance of human von Willebrand factor and factor VIII by liver sinusoidal endothelial cells, In: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2015, 13:252.
111. Ogiwara K., Swystun L., Brown C., Notley C., Ojala J., Tryggvason K., et al. Scavenger receptor class A member 5 (SCARA5) binds and internalizes VWF in vitro: a novel candidate VWF clearance receptor, In: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2015, 13:222.